Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Total revenues	$ 97,529	$ 88,845
Operating expenses:
Research and development	10,822	15,484
Selling, general and administrative	28,861	27,652
Restructuring expenses		311
Total operating expenses	39,683	43,447
Income from operations	57,846	45,398
Other (expense) income:
Interest expense	(2,341)	(7,626)
Interest and investment income	230	196
Gain on derivatives	730	2,390
Other expense, net	(1,381)	(5,040)
Income before income taxes	56,465	40,358
Income tax expense	(17,664)	(432)
Net income	38,801	39,926
Comprehensive income	$ 38,801	$ 39,926
Net income per share - basic (in dollars per share)	$ 0.25	$ 0.25
Net income per share - diluted (in dollars per share)	$ 0.21	$ 0.25
Weighted average shares used in computing net income per share - basic (in shares)	157,821	160,967
Weighted average shares used in computing net income per share - diluted (in shares)	189,540	162,347
Collaborative arrangements revenue
Revenues:
Total revenues	$ 97,529	$ 88,665
Sale of active pharmaceutical ingredient
Revenues:
Total revenues		$ 180